The cardioprotective effects of caffeic acid phenethyl ester (CAPE) on myocardial ischemia/reperfusion (I/R) injury by Castellano, Andrew et al.
The cardioprotective effects of caffeic acid phenethyl ester (CAPE) 
on myocardial ischemia/reperfusion (I/R) injury 
 Andrew J. Castellano, Tarah Kuhn, Stephanie Liu, Kevin Kucharski, Joseph Venditto,  Daniel Kuo, Robert Barsotti, Lindon H. Young, Qian Chen. 
Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine 
4170 City Avenue, Philadelphia, PA 19131 
 
Reperfusion injury is the acceleration of heart damage which occurs 
during the reintroduction of coronary blood flow to a prolonged ischemic 
area [1]. Oxidative stress is a major cause of reperfusion injury by 
reducing the bioavailability of nitric oxide (NO), damaging cellular 
function leading to cell death/apoptosis. To date, there is no effective 
clinical treatment for reperfusion injury. CAPE is an active component of 
propolis collected from honeybee hives that exhibits both anti-oxidant 
and anti-inflammatory effects [2]. Recently, CAPE when given prior to 
ischemia was found to be cardioprotective against I/R injury [3,4]. The 
beneficial effects of CAPE are possibly mediated by upregulating heme 
oxygenase-1 and/or increased bioavailability of NO. However, the effects 
of CAPE when given at reperfusion in myocardial I/R (MI/R) injury has 
not been evaluated. This study tested the effects of CAPE on 
postreperfused cardiac function, infarct size, and putative mechanisms in 
an isolated rat MI/R model when given at reperfusion. 
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CONCLUSION  
Our results suggest that CAPE when given at reperfusion improves post-
reperfused contractile function and reduces infarct size. The 
cardioprotective effects of CAPE may be mediated by increasing NO 
bioavailability and/or heme oxygenase-1 activity. The effects of CAPE on 
mitochondrial function during I/R will be determined in future experiments.  
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Isolated Rat Heart MI/R Experiments:  Hearts were isolated from male 
Sprague Dawley rats (275-325g, Charles River, Springfield, MA) via 
Langendorff heart preparation as previously described [5]. Experimental 









A pressure transducer (SPR-524, Millar Instruments, Inc., Houston, TX) 
was inserted into the left ventricle to record cardiac function (e.g. left 
ventricular end systolic and diastolic pressure (LVESP & LVEDP, 
respectively). Coronary flow was measured by a flow probe (T106, 
Transonic Systems, Inc., Ithaca, NY) which was placed in the inflow 
perfusion line. Data was recorded using a Powerlab Station acquisition 
system (ADInstruments, Grand Junction, CO) every 5 min during 
baseline and reperfusion.   
Determination of Infarct Size: At the end of the experiment, the left 
ventricle of the heart was sectioned into 2 mm thick slices that were 
subjected to 1% triphenyltetrazolium chloride (TTC) staining to detect 
infarcted (unstained) and viable (stained brick red) areas.  Infarct size 
was expressed as the percentage of infarcted tissue weight to the total 
tissue weight as previously described [5]. 
Statistical Analysis: All data in the figures are presented as means ± 
S.E.M. The data was analyzed by ANOVA using post hoc analysis with 
Student-Newman-Keuls test. p<0.05 are considered to be statistically 
significant.  
HYPOTHESIS 
In this study, we hypothesized that CAPE when given at reperfusion 
would attenuate I/R induced cardiac contractile dysfunction and infarct 
size. Moreover, the cardioprotective effects of CAPE would be inhibited 
by a non-selective NO synthase inhibitor (NG-nitro-L-arginine methyl 
ester (L-NAME)) or a heme oxygenase-1 inhibitor (tin protoporphyrin 
(SnPP)).  
  
CAPE (n=5) restored LVDP to 85 ± 14% of baseline value at 60 min 
post-reperfusion compared to untreated control I/R hearts (n=11) that 
only recovered to 45 ± 8% of baseline value (p<0.01). 
 
CAPE (n=5) restored LVESP to 139 ± 14% of baseline value at 60 min 
post-reperfusion compared to untreated control I/R hearts (n=11) that 
only recovered to 106 ± 7% of baseline value (p<0.05). 
 
CAPE (n=5) restored dP/dtmax to 60 ± 11% of baseline value at 60 min 
post-reperfusion compared to untreated control I/R hearts (n=11) that 
only recovered to 33 ± 5% of baseline value (p<0.05). 
  
CAPE (n=5) also significantly reduced infarct size to 19 ± 2% 
compared to 37 ± 3% in untreated control I/R hearts (n=11) (p<0.05). 
  
A non-selective nitric oxide synthase inhibitor, L-NAME (50 µM, n=5); 
or a heme oxygenase-1 inhibitor, SnPP (20 µM, n=5), significantly 
abolished the cardioprotective effects of CAPE (all p<0.05).   
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Figure 5. Time course of LVESP for  Control I/R, I/R + 40 μM CAPE, 
I/R + 40 μM CAPE + 50 μM L-NAME, and I/R + 40 μM CAPE + 20 
μM SnPP groups. (* p< 0.05 vs. I/R; # p<0.05, ##p< 0.01 vs. I/R + 40 
μM CAPE) 
 
Figure 3. Time course of LVDP (Difference between LVESP and 
LVEDP)  for Control I/R, I/R + 40 μM CAPE, I/R + 40 μM CAPE + 50 
μM L-NAME, and I/R + 40 μM CAPE + 20 μM SnPP groups. (* p< 
0.05, ** p< 0.01 vs. I/R; ##p< 0.01 vs. I/R + 40 μM CAPE) 
 
Figure 4. Time course of dP/dtmax (maximal rate of left ventricular 
systolic pressure over time) for Control I/R, I/R + 40 μM CAPE, I/R + 40 
μM CAPE + 50 μM L-NAME, and I/R + 40 μM CAPE + 20 μM SnPP 
groups. (* p< 0.05, ** p< 0.01 vs. I/R; # p<0.05, ##p< 0.01 vs.  




The representative TTC 
staining pictures and 
summarized infarct size 
graph for experimental 
groups. 40 μM CAPE 
exhibited significantly lower 
infarct size compared to the 
I/R, 40 μM CAPE + 50 μM  L-
NAME, and 40 μM CAPE + 
20 μM SnPP groups.  
(** p< 0.01 vs. I/R;   
##p< 0.01 vs. I/R + 40 μM 
CAPE) 
Figure 1. Chemical structure 
of  CAPE. Adapted from 
Murtaza et al, 2014. 
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Figure 2.  
Flow diagram of  
experimental 
protocol.  
